ret finger protein like 4AGenealiases: RFPL4 · RNF210
Q-omics provides the consensus-scored RFPL4A profile across patient tissues and cancer cell-line models. RFPL4A expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RFPL4A is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, RFPL4A RNA expression shows 9,652 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KIRC, and TGCT as cancer lineages where RFPL4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RFPL4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RFPL4A survival associations across molecular data types. RFPL4A RNA expression shows survival associations in the most cancer types (14), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RFPL4A RNA expression–survival associations across cancer types. High RFPL4A expression shows unfavorable associations in ACC, LGG, CHOL, LUSC and KIRP, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .018). Together, the overview and detailed table identify ACC as the clearest survival context for RFPL4A RNA expression.
This table summarizes RFPL4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RFPL4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RFPL4A shows lower tumor expression in KICH, LUSC, COAD and THCA and higher tumor expression in KIRC. The KIRC box plot shows higher RFPL4A RNA expression in tumor versus normal tissue (log2 FC = +0.078, t-test p = .020).
This table shows molecular features associated with RFPL4A in patient tissues and cancer cell lines. In patient samples, RFPL4A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RFPL4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LARGE_INTESTINE.
